Clinical trials: Graft -Versus-host-disease
Bone Marrow Transplant Infection, Bone Marrow Transplant Complications
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
Interventional non-randomized trial. The duration of study will be 47 months. After haploidentical transplantation, patients without complications, mainly a GVHD ≥ grade 2, will receive mDLI.
- Conditions
- Bone Marrow Transplant Infection, Bone Marrow Transplant Complications, Graft Vs Host Disease, Infection
- Trial name
- NCT04687982
- Testing
- modified donor lymphocytes infusion (mDLI)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Istituto Clinico Humanitas
Oral Chronic Graft vs Host Disease
Clobetasol for Oral Graft-Versus-Host Disease
Background: Oral graft-versus-host disease (GVHD) is a possible complication of bone marrow transplants. It is the result of the donor cells trying to attack the recipients body.
- Trial name
- NCT01557517
- Testing
- Clobetasol Oral Rinse
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cough
The Utility of feNO in the Differential Diagnosis of Chronic Cough
In this study the investigators wish to explore the difference in 24 hr. cough counts measured using the Hull Automated Cough Counter (HACC), from baseline and after two weeks treatment with either montelukast or prednisolone in…
- Trial name
- TUF (NCT02479074)
- Testing
- Montelukast (High FeNO group), Prednisolon, Montelukast (High FeNO), Montelukast (Low FeNO group)
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Graft-versus-host Disease
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral…
- Trial name
- NCT05622318
- Testing
- Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Medical College of Wisconsin
Pleural Effusions, Chronic, Congestive Heart Failure
Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial
Congestive heart disease (CHF) can frequently cause transudative pleural effusions, some of which do not completely resolve with diuretics alone.
- Conditions
- Pleural Effusions, Chronic, Congestive Heart Failure, Shortness of Breath
- Trial name
- TREAT-CHF (NCT03696524)
- Testing
- tunneled pleural catheter
- Where
- United States
- Sponsor
- University of California, Los Angeles
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
T-cell Lymphoma, Graft Versus Host Disease
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma.
- Conditions
- T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma
- Trial name
- NCT07356245
- Testing
- Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Dry Eye
IVIG-eye Drops Treatment for Dry Eye Disease
The main objective of this study is to establish whether patients with Dry Eye Disease are able to safely tolerate receiving Intravenous Immunoglobulin (IVIG) eye drops two times a day for eight weeks (primary 'safety and…
- Trial name
- NCT03992482
- Testing
- Intravenous Immune Globulin (IVIG)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sandeep Jain, MD
Graft Versus Host Disease
A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)
The present study is multi center, phase I/IIa clinical trial to evaluate the safety and pharmacodynamics of investigational Product (VM-001) in patients with graft-versus-host disease(GvHD).
- Trial name
- NCT05276076
- Testing
- VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg
- Volunteers
- 12 people
- Sponsor
- ViGenCell Inc.
Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
This phase II trial studies how well ustekinumab works in preventing acute graft-versus-host disease after unrelated donor hematopoietic cell transplant.
- Trial name
- NCT04572815
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab
- Where
- 4 sites in United States
- Volunteers
- 116 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic and Episodic Headache, Headache Disorders
PERSONOLOGICAL STRUCTURE, COGNITIVE FUNCTIONS AND CENTRAL SENSITIZATION IN HEADACHE
Headache, in its episodic and chronic forms, cannot be considered solely as an isolated neurological symptom, but as a complex condition of a bio-psycho-social nature.
- Trial name
- AURA (NCT07268768)
- Testing
- Neuropsychological assessment
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Allogeneic Stem Cell Transplantation, GVHD
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation
Graft versus Host disease ( GVHD) is one of the major complications of Allogeneic Stem Cell Transplantation. Acute GVHD develops early ( within 2to 3 months) after transplantation and is the leading cause of death of transplanted…
- Trial name
- NCT03233659
- Where
- Italy
- Volunteers
- 177 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Leukemia, Chronic Lymphocytic Leukemia
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
This phase II trial studies how well tacrolimus, bortezomib, and anti-thymocyte globulin (thymoglobulin) work in preventing low toxicity graft versus host disease (GVHD) in patients with blood cancer who are undergoing donor stem…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02877082
- Testing
- Thymoglobulin, Bortezomib, Tacrolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Chronic Graft-versus-host-disease
Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease
Chronic graft-versus-host disease (cGVHD) affects 30 to 70% of Allogeneic Hematopoietic Cell Transplantation, decreases the quality of life, and increases mortality.
- Trial name
- NCT05348096
- Testing
- Low-dose ibrutinib
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Graft Versus Host Disease
Alefacept for Prevention of Graft Versus Host Disease (GVHD)
Alefacept (AMEVIVE®) is an immunosuppressive dimeric fusion protein. It was shown to interfere with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction.
- Trial name
- NCT00361413
- Testing
- Alefacept (AMEVIVE®), control group
- Where
- Israel
- Volunteers
- 26 people
- Sponsor
- Hadassah Medical Organization
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Sinusitis, Chronic, Cystic Fibrosis With Other Manifestations
SynRinse Irrigation Pilot (SIP) Trial
Assess if the use of SYNRINSE can improve short-term subjective and objective outcome measures after one week in patients with active Chronic Rhinosinusitis (CRS) who have had prior sinus surgery.
- Trial name
- NCT03154541
- Testing
- Synrinse
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Leukaemia (Chronic)
What is the Impact of TKI on Thyroid Function in CML Patients?
Evaluation of the impact of various TKI on thyroid function in patients diagnosed with cml
- Trial name
- NCT07200882
- Volunteers
- 76 people
- Sponsor
- Assiut University
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Back Pain Lower Back Chronic
Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain.
Low back pain is the second most common reason for medical consultation in France and affects 60 to 80% of the working population.
- Trial name
- MeLoPe (NCT07403500)
- Testing
- Spinal or peripheral manipulation of the lower back to treat lower back pain
- Where
- France
- Volunteers
- 416 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.